INS and familial pancreatic carcinoma: In the new-user design, HRs for pancreatic cancer in GLP-1RA users vs basal insulin users were 0.67 (95% CI, 0.41-1.07) over the full follow-up period, 0.84 (95% CI, 0.46-1.52) omitting the first year of follow-up, and 0.52 (95% CI, 0.19-1.41) omitting the first 4 years of follow-up (eTable 3 in Supplement 1).